title: Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers.
abstract: The activity of recombinant human growth hormone (rhGH) in enhancing CD34(+) cell mobilization elicited by chemotherapy plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) was evaluated in 16 hard-to-mobilize patients, that is, those achieving a peak of circulating CD34+ cells 10/microL or less, or a collection of CD34(+) cells equal to or less than 2 x 10(6)/kg. Patients who had failed a first mobilization attempt with chemotherapy plus rhG-CSF (5 microg/kg/d) were remobilized with chemotherapy plus rhG-CSF and rhGH (100 microg/kg/d). As compared with rhG-CSF, the combined rhGH/rhG-CSF treatment induced significantly higher (P < or =.05) median peak values for CD34(+) cells/microL (7 versus 29), colony-forming cells (CFCs)/mL (2154 versus 28,510), and long-term culture-initiating cells (LTC-ICs)/mL (25 versus 511). Following rhG-CSF and rhGH/rhG-CSF, the median yields of CD34(+) cells per leukapheresis were 1.1 x 10(6)/kg and 2.3 x 10(6)/kg (P < or =.008), respectively; the median total collections of CD34(+) cells were 1.1 x 10(6)/kg and 6 x 10(6)/kg (P < or =.008), respectively. No specific side effect could be ascribed to rhGH, except a transient hyperglycemia occurring in 2 patients. Reinfusion of rhGH/rhG-CSF-mobilized cells following myeloablative therapy resulted in prompt hematopoietic recovery. In conclusion, our data demonstrate that in poor mobilizers addition of rhGH to rhG-CSF allows the patients to efficiently mobilize and collect CD34(+) cells with maintained functional properties.
authors.affiliation: Cristina Gandini Oncology Unit, Istituto Nazionale Tumori, and Department of Hematology and Medical Oncology, University of Milano, Milan, Italy. carmelo.carlostella@unimi.it
authors.forename: Carmelo
authors.initials: C
authors.lastname: Carlo-Stella
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Nicola
authors.forename: Raffaella
authors.initials: R
authors.lastname: Milani
authors.forename: Anna
authors.initials: A
authors.lastname: Guidetti
authors.forename: Michele
authors.initials: M
authors.lastname: Magni
authors.forename: Marco
authors.initials: M
authors.lastname: Milanesi
authors.forename: Paolo
authors.initials: P
authors.lastname: Longoni
authors.forename: Paola
authors.initials: P
authors.lastname: Matteucci
authors.forename: Franca
authors.initials: F
authors.lastname: Formelli
authors.forename: Fernando
authors.initials: F
authors.lastname: Ravagnani
authors.forename: Paolo
authors.initials: P
authors.lastname: Corradini
authors.forename: Alessandro M
authors.initials: AM
authors.lastname: Gianni
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002452:Cell Count; D004359:Drug Therapy, Combination; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000633:toxicity; D006410:Hematopoiesis; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D019382:Human Growth Hormone / Q000008:administration & dosage* / Q000633:toxicity; D006801:Humans; D007937:Leukapheresis / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D016179:Granulocyte Colony-Stimulating Factor